10.1371/journal.pgen.1008057.g006
Nadège Liaud
Nadège
Liaud
Max A. Horlbeck
Max A.
Horlbeck
Luke A. Gilbert
Luke A.
Gilbert
Ketrin Gjoni
Ketrin
Gjoni
Jonathan S. Weissman
Jonathan
S. Weissman
Jamie H. D. Cate
Jamie
H. D. Cate
Comparison of PF8503 and homoharringtonine CRISPRi screens.
Public Library of Science
2019
compound
ubiquitin binding protein ASCC 2
translation quality control proteins Pelota
PCSK 9 translational inhibitor
LDL
genome-wide CRISPRi screen
HBS 1L
PF 8503 treatment
ribosome quality control pathways
ASCC 3 acts
PELO
stall protein synthesis
2019-03-15 17:39:07
Figure
https://plos.figshare.com/articles/figure/Comparison_of_PF8503_and_homoharringtonine_CRISPRi_screens_/7853108
<p>(A) Comparison of gene knockdowns that had significant effects on compound toxicity (Rho phenotype) in CRISPRi screens in the presence of homoharringtonin (HHT) or PF8503. Knockdowns with significant effects in the presence of HHT alone (HHT only, grey), PF8503 alone (PF8503 only, red), or in the presence of either compound (PF8503+HHT, blue) are shown. (B) Venn diagram of significant genes in the HHT and PF8503 CRISPRi screens. (C) Pathways enriched in the common and distinct collection of genes in the HHT and PF8503 CRISPRi screens. Gene count observed corresponds to the number of genes attributed to this pathway by STRING, as a percentage of the total number of genes attributed to a pathway (D). Phenotypes obtained in K562_dCas9-KRAB competition experiments (scrambled sgRNA as control), with cells treated with three different translation inhibitors: 20 nM HHT, 7.5 μM PF8503, or 7.5 μM PF846. Included are examples predicted to be part of translation quality control (ASCC2, ASCC3, HBS1L, NEMF), RNA transport (ALYREF) and ubiquitin-mediated proteolysis (UBR5). Experiments carried in biological triplicate, with mean and standard deviation shown.</p>